ImageneBio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
27.1%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$4.10next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q4 and Full Year 2026 Financial Results | 16 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly117.2MTarget: Sufficient to fund operations into Q1 2028
Phase 2b ADAPTIVE Trial Enrollment QuarterlyTarget: ~220 patients
Quarterly R&D Expenses Quarterly6MTarget: Manageable cash burn within runway projections
Watch Items
- Topline data readout from the Phase 2b ADAPTIVE trial of IMG-007 in moderate-to-severe atopic dermatitisTrigger: Q4 2027Action: Evaluate efficacy (EASI percent change from baseline at 24 weeks) and safety profile (specifically pyrexia/chills) to determine phase 3 readiness.
- Initiation of Phase 2 clinical trial of IMG-007 in alopecia areataTrigger: Second half of 2026Action: Monitor trial protocol finalization, site activation, and first patient dosed.
- Cash runway depletion and capital requirementsTrigger: Q1 2028Action: Secure additional dilutive or non-dilutive financing prior to mid-2027 to maintain operational continuity.
Research as of 19 Jun 2026